Progression of endocrine therapies for breast cancer: where are we headed?

References

• Ries L, Harkins D, Krapcho M. Cancer SEER Statistics Review, 1975–2003. National Cancer Insititute, Bethesda, MD, USA (2006).
   Google Scholar
• Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J. Clin. Oncol.21(1), 28–34 (2003).
   PubMed Web of Science ®Google Scholar
• Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet2, 104–107 (1896).
   Google Scholar
• Rose C, Mouridsen HT. Treatment of advanced breast cancer with tamoxifen. Recent Results Cancer Res.91, 230–242 (1984).
   PubMedGoogle Scholar
• Mauri D, Pavlidis N, Polyzos NP et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J. Natl Cancer Inst.98(18), 1285–1291 (2006).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol.21(11), 2101–2109 (2003).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Osborne CK. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med.339(22), 1609–1618 (1998).
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351(9114), 1451–1467 (1998).
   PubMed Web of Science ®Google Scholar
• Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev.25(1), 45–71 (2004).
   PubMed Web of Science ®Google Scholar
• Friedman ZY. Recent advances in understanding the molecular mechanisms of tamoxifen action. Cancer Invest.16(6), 391–396 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90(18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7), 637–645 (1999).
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat.65(2), 125–134 (2001).
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23), 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Simpson ER, Mahendroo MS, Means GD et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev.15(3), 342–355 (1994).
   PubMed Web of Science ®Google Scholar
• Cheung KL. Endocrine therapy for breast cancer: an overview. Breast 16(4), 327–343 (2007).
   PubMedGoogle Scholar
• Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3), 223–234 (2007).
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J. Clin. Oncol.25(5), 4864–4892 (2007).
   Google Scholar
• Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann. Oncol.16(5), 707–715 (2005).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Jacobs S, Aherne J et al. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Clin. Ther.14(Suppl. A), 97–103 (1992).
   PubMedGoogle Scholar
• Nicholson RI, Walker KJ, Turkes A et al. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J. Steroid Biochem.23(5B), 843–847 (1985).
   Google Scholar
• Taylor CW, Green S, Dalton WS et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J. Clin. Oncol.16(3), 994–999 (1998).
   PubMed Web of Science ®Google Scholar
• Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci.106(Pt 4), 1377–1388 (1993).
   PubMed Web of Science ®Google Scholar
• Howell A, DeFriend D, Robertson J et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet345(8941), 29–30 (1995).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Sano M, Ohno S et al. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study. Anticancer Res.24(2C), 1275–1280 (2004).
   Google Scholar
• Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol.22(9), 1605–1613 (2004).
   PubMed Web of Science ®Google Scholar
• Howell A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer104(2), 236–239 (2005).
   PubMed Web of Science ®Google Scholar
• Ingle JN, Suman VJ, Rowland KM et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol.24(7), 1052–1056 (2006).
   PubMed Web of Science ®Google Scholar
• Haller DG, Glick JH. Progestational agents in advanced breast cancer: an overview. Semin. Oncol.13(Suppl. 4), 2–8 (1986).
   PubMed Web of Science ®Google Scholar
• Gregory EJ, Cohen SC, Oines DW et al. Megestrol acetate therapy for advanced breast cancer. J. Clin. Oncol.3(2), 155–160 (1985).
   PubMed Web of Science ®Google Scholar
• Blossey HC, Wander HE, Koebberling J et al. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54(Suppl. 6), 1208–1215 (1984).
   PubMed Web of Science ®Google Scholar
• Mattsson W. Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res. Treat.3(2), 231–235 (1983).
   PubMed Web of Science ®Google Scholar
• Ingle JN, Ahmann DL, Green SJ et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am. J. Clin. Oncol.5(2), 155–160 (1982).
   PubMed Web of Science ®Google Scholar
• Carlini P, Bria E, Giannarelli D et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 104(7), 1335–1342 (2005).
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol.18(22), 3748–3757 (2000).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Bonneterre J, Buzdar A et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer39(12), 1684–1689 (2003).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol.18(22), 3758–3767 (2000).
   PubMed Web of Science ®Google Scholar
• Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, Phase III study. Am. J. Clin. Oncol.26(3), 317–322 (2003).
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol.20(3), 751–757 (2002).
   PubMed Web of Science ®Google Scholar
• Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – a randomized Phase III trial of the EORTC Breast Group. J. Clin. Oncol.14, 515 (2004) (Abstract).
   Google Scholar
• Ingle JN, Krook JE, Green SJ et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J. Clin. Oncol.4(2), 178–185 (1986).
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Thomson DB, Myers RE et al. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat. Rep.64(6–7), 787–796 (1980).
   PubMedGoogle Scholar
• Sawka CA, Pritchard KI, Shelley W et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res. Treat.44(3), 211–215 (1997).
   PubMed Web of Science ®Google Scholar
• Buchanan RB, Blamey RW, Durrant KR et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J. Clin. Oncol.4(9), 1326–1330 (1986).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Perrotta A et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann. Oncol.5(4), 337–342 (1994).
   PubMed Web of Science ®Google Scholar
• Jonat W, Kaufmann M, Blamey RW et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur. J. Cancer 31A(2), 137–142 (1995).
   PubMedGoogle Scholar
• Klijn JG, Beex LV, Mauriac L et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J. Natl Cancer Inst.92(11), 903–911 (2000).
   PubMed Web of Science ®Google Scholar
• Klijn JG, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J. Clin. Oncol.19(2), 343–353 (2001).
   PubMed Web of Science ®Google Scholar
• Forward DP, Cheung KL, Jackson L et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br. J. Cancer 90(3), 590–594 (2004).
   PubMed Web of Science ®Google Scholar
• Celio L, Martinetti A, Ferrari L et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res.19(3B), 2261–2268 (1999).
   PubMed Web of Science ®Google Scholar
• Carlson RW, Schurman CM, Rivera E et al. Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer. J. Clin. Oncol.25(Suppl. 18), 1030 (2007) (Abstract).
   Google Scholar
• Cheung KL, Winterbottom L, Owers R et al. Goserelin plus anastrozole as first-line endocrine therapy for premenopausal women with oestrogen receptor (ER) positive advanced breast cancer (ABC) J. Clin. Oncol.23(Suppl. 16), 731 (2005) (Abstract).
   Google Scholar
• Thurlimann B, Robertson JF, Nabholtz JM et al. Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur. J. Cancer 39(16), 2310–2317 (2003).
   PubMed Web of Science ®Google Scholar
• Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J. Clin. Oncol.18(11), 2234–2244 (2000).
   PubMed Web of Science ®Google Scholar
• Bertelli G, Garrone O, Merlano M et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69(6), 471–477 (2005).
   PubMed Web of Science ®Google Scholar
• Gradishar W, Chia S, Piccart M et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, Phase III trial in postmenopausal women with advanced breast cancer. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract 12).
   Google Scholar
• Mustacchi G, Ceccherini R, Milani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the Phase III randomized controlled multicenter GRETA trial. Ann. Oncol.14(3), 414–420 (2003).
   PubMed Web of Science ®Google Scholar
• Fennessy M, Bates T, MacRae K et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br. J. Surg.91(6), 699–704 (2004).
   PubMed Web of Science ®Google Scholar
• Semiglazov VF, Semiglazov V, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer. J. Clin. Oncol.22(Suppl. 14), 519 (2004) (Abstract).
   Google Scholar
• Semiglazov VF, Semiglazov VV, Ivanov VG et al. Preoperative hormonal therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients. Eur. J. Cancer2(3), 71 (2004) (Abstract).
   Google Scholar
• Dixon JM, Renshaw L, Bellamy C et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin. Cancer Res.6(6), 2229–2235 (2000).
   PubMed Web of Science ®Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol.12(11), 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol.19(18), 3808–3816 (2001).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Ebbs SR, Dixon JM et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists. J. Clin. Oncol.23(11), 2477–2492 (2005).
   PubMed Web of Science ®Google Scholar
• Dowsett M, A’Hern R, Smith I. Ki-67 after 2 weeks endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract 46).
   Google Scholar
• Semiglazov V, Kletsel A, Semiglazov V et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0). J. Clin. Oncol.23(Suppl. 16), 530 (2005) (Abstract).
   Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol.23(22), 5108–5116 (2005).
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared with Tamoxifen (PROACT) trial. Cancer 106(10), 2095–2103 (2006).
   PubMed Web of Science ®Google Scholar
• Llombart A, Ruiz A, Lopez-Guerrero JA et al. Obejctive response to neoadjuvant letrozole predicts distant disease free survival in postmenopausal women with stage II–III ER/PgR-positive breast cancer. Ann. Oncol.9(11), 252 (2006) (Abstract).
   Google Scholar
• Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324), 2131–2139 (2002).
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.353(26), 2747–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin. Cancer Res.12(3 Pt 2), S1037–S1048 (2006).
   PubMed Web of Science ®Google Scholar
• Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl Cancer Inst.97(17), 1254–1261 (2005).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol.23(30), 7512–7517 (2005).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Allred D. On behalf of the TransATAC Investigators, relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract 48).
   Google Scholar
• Viale G, Regan M, Dell’Orto P et al. Central review of ER, PgR and HER-2 in BIG 1–98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract 44).
   Google Scholar
• Duffy S, Jackson TL, Lansdown M et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum. Reprod.21(2), 545–553 (2006).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561), 559–570 (2007).
   PubMed Web of Science ®Google Scholar
• Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol.7(12), 991–996 (2006).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol.23(22), 5138–5147 (2005).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484), 455–462 (2005).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Gnant M, Greil R et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-year-analysis of ABCSG Trial 8. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract 13).
   Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol.14(10), 2738–2746 (1996).
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst.93(9), 684–690 (2001).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med.349(19), 1793–1802 (2003).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a) J. Clin. Oncol.23(Suppl. 16), 527 (2005) (Abstract).
   Google Scholar
• Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J. Clin. Oncol.24(16), 2444–2447 (2006).
   PubMed Web of Science ®Google Scholar
• Kendall A, Dowsett M, Folkerd E et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann. Oncol.17(4), 584–587 (2006).
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453), 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol.24(33), 5305–5312 (2006).
   PubMed Web of Science ®Google Scholar
• Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J. Clin. Oncol.24(22), 3629–3635 (2006).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Ambroisine L, Davidson N et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369(9574), 1711–1723 (2007).
   PubMed Web of Science ®Google Scholar
• Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol.20(24), 4628–4635 (2002).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Hausmaninger H, Kubista E et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer – Austrian Breast and Colorectal Cancer Study Group trial 5. J. Clin. Oncol.20(24), 4621–4627 (2002).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst.99(2), 167–170 (2007).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• van’t Veer LJ, Dai H, van MJ de Vijver et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson NE, AM O’Neill, Vukov AM et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J. Clin. Oncol.23(25), 5973–5982 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson NE, A O’Neill, Vukov A et al. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group Phase III intergroup trial (E5188, INT-0101). J. Clin. Oncol.22, 15 (2003).
   PubMedGoogle Scholar
• Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor–HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst.96(12), 926–935 (2004).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Hutcheson IR, Knowlden JM et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin. Cancer Res.10(1 Pt 2), S346–S354 (2004).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smith I , Skene A et al. Biological and clinical outcomes from a Phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223). J. Clin. Oncol.24(Suppl. 18), 515 (2006) (Abstract).
   Google Scholar
• Mackey JR, Kaufman B, Clemens M et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract).
   Google Scholar
• Chu I, >Blackwell K, Chen S et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res.65(1), 18–25 (2005).
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19(56), 6680–6686 (2000).
   PubMed Web of Science ®Google Scholar
• deGraffenried LA, Friedrichs WE, Russell DH et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin. Cancer Res.10(23), 8059–8067 (2004).
   PubMed Web of Science ®Google Scholar
• Rudolf J, Boulay A, Zumstein-Mecker S et al. The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas. Proc. Am. Assoc. Cancer Res.45, 5619 (2004) (Abstract).
   Google Scholar
• Tabernero J, Rojo F, Burris H et al. A Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. J. Clin. Oncol.23(Suppl. 16), 3007 (2005) (Abstract).
   Web of Science ®Google Scholar